Boltwood Capital Management Boosts Position in Bristol-Myers Squibb Company (BMY)
Boltwood Capital Management increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,205 shares of the biopharmaceutical company’s stock after buying an additional 300 shares during the quarter. Boltwood Capital Management’s holdings in Bristol-Myers Squibb were worth $1,014,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. State Street Corp grew its holdings in shares of Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Bristol-Myers Squibb by 0.8% during the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after buying an additional 178,436 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Bristol-Myers Squibb by 4.3% during the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after buying an additional 335,795 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares in the last quarter. Institutional investors and hedge funds own 68.80% of the company’s stock.
Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.33% during mid-day trading on Friday, reaching $62.48. The company had a trading volume of 10,407,558 shares. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47. The stock has a market capitalization of $102.46 billion, a PE ratio of 22.82 and a beta of 1.18. The company’s 50-day moving average is $58.56 and its 200-day moving average is $55.95. Bristol-Myers Squibb also was the target of some unusual options trading on Thursday. Investors acquired 781 put options on the stock. This is an increase of 117% compared to the typical volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the company earned $0.69 earnings per share. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.50%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
A number of research analysts recently issued reports on BMY shares. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective for the company in a report on Monday, June 5th. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. Finally, Cowen and Company set a $65.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $62.66.
In related news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.